Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients ... 7thSpace Interactive (press release) For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been ... |
